Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist

International Journal of Cancer

Volumn 138, Issue 8, 2016, Pages 2021-2029

  Toledo, Míriam ^a   Busquets, Sílvia ^a   Penna, Fabio ^a   Zhou, Xiaolan ^b   Marmonti, Enrica ^a   Betancourt, Angelica ^a   Massa, David ^a   López Soriano, Francisco J ^a   Han, H Q ^b   Argilés, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b AMGEN INC   (United States)

Author keywords

ActRIIB; antimyostatin; cancer cachexia; formoterol; multitherapy; skeletal muscle

Indexed keywords

ACTIVIN RECEPTOR 2; CYTOKINE RECEPTOR ANTAGONIST; FORMOTEROL; MYOSTATIN; PHENYLALANINE; SACTRIIB; TYROSINE; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR TYPE II-B; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL FUMARATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FOOD INTAKE; GRIP STRENGTH; LUNG CARCINOMA; MALE; METASTASIS; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SURVIVAL; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; LEWIS CARCINOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ACTIVIN RECEPTORS, TYPE II; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; CACHEXIA; CARCINOMA, LEWIS LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORMOTEROL FUMARATE; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84958915621     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29930     Document Type: Article

References (46)

1. Muscaritoli M, Bossola M, Aversa Z, et al., Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 2006; 42: 31-41.
2. Loberg RD, Bradley DA, Tomlins SA, et al., The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007; 57: 225-41.
3. Fearon KCH., Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44: 1124-32.
4. Fearon K, Arends J, Baracos V., Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10: 90-9.
5. Argiles JM, Alvarez B, Lopez-Soriano FJ., The metabolic basis of cancer cachexia. Med Res Rev 1997; 17: 477-98.
6. Wolfe RR., The underappreciated role of muscle in health and disease. Am J Clin Nutr 2006; 84: 475-82.
7. Smith KL, Tisdale MJ., Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 1993; 67: 680-5.
8. Costelli P, Carbó N, Tessitore L, et al., Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest 1993; 92: 2783-9.
9. Gallagher IJ, Stephens NA, MacDonald AJ, et al., Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin Cancer Res 2012; 18: 2817-27.
10. Llovera M, García-Martínez C, Agell N, et al., Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett 1994; 338: 311-8.
11. Zhao J, Brault JJ, Schild A, et al., FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6: 472-83.
12. Sandri M, Sandri C, Gilbert A, et al., Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
13. Penna F, Baccino FM, Costelli P., Coming back: autophagy in cachexia. Curr Opin Clin Nutr Metab Care 2014; 17: 241-6.
14. Williams AB, Decourten-Myers GM, Fischer JE, et al., Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J 1999; 13: 1435-43.
15. Smith IJ, Aversa Z, Hasselgren P-O, et al., Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. Muscle Nerve 2011; 43: 410-4.
16. Costelli P, Reffo P, Penna F, et al., Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005; 37: 2134-46.
17. Van Royen M, Carbó N, Busquets S, et al., DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun 2000; 270: 533-7.
18. Tisdale MJ., Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410.
19. Argilés JM, Busquets S, Toledo M, et al., The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 263-8.
20. Stitt TN, Drujan D, Clarke BA, et al., The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395-403.
21. Penna F, Costamagna D, Fanzani A, et al., Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One 2010; 5: e13604
22. Lee SJ, McPherron AC., Myostatin and the control of skeletal muscle mass. Curr Opin Genet Dev 1999; 9: 604-7.
23. Sharma M, Langley B, Bass J, et al., Myostatin in muscle growth and repair. Exerc Sport Sci Rev 2001; 29: 155-8.
24. Liu C-M, Yang Z, Liu C-W, et al., Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 2008; 15: 155-60.
25. Bonetto A, Penna F, Minero VG, et al., Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009; 9: 608-16.
26. Benny Klimek ME, Aydogdu T, Link MJ, et al., Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010; 391: 1548-54.
27. Zhou X, Wang JL, Lu J, et al., Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-43.
28. Busquets S, Toledo M, Orpí M, et al., Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012; 3: 37-43.
29. Carbó N, López-Soriano J, Tarragó T, et al., Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 1997; 115: 113-8.
30. Moore RH, Khan A, Dickey BF., Long-acting inhaled beta2-agonists in asthma therapy. Chest 1998; 113: 1095-108.
31. Busquets S, Toledo M, Sirisi S, et al., Formoterol and cancer muscle wasting in rats: effects on muscle force and total physical activity. Exp Ther Med 2011; 2: 731-5.
32. Greig CA, Johns N, Gray C, et al., Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer 2014; 22: 1269-75.
33. Donati MB, Mussoni L, Poggi A, et al., Growth and metastasis of the Lewis lung carcinoma in mice defibrinated with batroxobin. Eur J Cancer 1978; 14: 343-7.
34. Toledo M, Busquets S, Sirisi S, et al., Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep 2011; 25: 189-93.
35. Emery PW, Lovell L, Rennie MJ., Protein synthesis measured in vivo in muscle and liver of cachectic tumor-bearing mice. Cancer Res 1984; 44: 2779-84.
36. Busquets S, Alvarez B, Llovera M, et al., Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. J Cell Physiol 2000; 184: 380-4.
37. Waalkes TP, Udenfriend S., A fluorometric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Med 1957; 50: 733-6.
38. Busquets S, Figueras MT, Fuster G, et al., Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004; 64: 6725-31.
39. Toledo M, Springer J, Busquets S, et al., Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014; 5: 315-20.
40. Tian M, Nishijima Y, Asp ML, et al., Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 2010; 37: 347-53.
41. Leto G, Incorvaia L, Badalamenti G, et al., Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006; 23: 117-22.
42. Antsiferova M, Huber M, Meyer M, et al., Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat Commun 2011; 2: 576
43. Panopoulou E, Murphy C, Rasmussen H, et al., Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res 2005; 65: 1877-86.
44. Pfitzenmaier J, Vessella R, Higano CS, et al., Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003; 97: 1211-6.
45. Wigmore SJ, Todorov PT, Barber MD, et al., Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000; 87: 53-8.
46. Bonetto A, Aydogdu T, Kunzevitzky N, et al., STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011; 6: e22538